Zacks.com on MSN3d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Vertex: Downgrading To A Hold As Upside Is Limited
Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...
Yahoo Finance21d
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
Vertex Pharmaceuticals presently features a Zacks Rank of #3 (Hold). From a valuation perspective, Vertex Pharmaceuticals is currently exchanging hands at a Forward P/E ratio of 7790.32.
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock ...
Business Insider16d
Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX ... The initiation of a Phase 3 trial for IgAN indicates progress, but the evaluation of ...
Arkadios Wealth Advisors Buys New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Arkadios Wealth Advisors bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in ...
Investing21d
Vertex shares hold as BMO reiterates stock target on pain drug update
The continued support comes after Vertex presented more detailed Phase 3 information on its non-opioid pain medication, Suzetrigine, at the Anesthesiology Meeting. The new data provided insights ...